## Prognostic Factors in Prostate Cancer ### Risk Stratification Framework Prostate cancer prognosis is determined by a combination of clinical, pathological, and molecular factors. The D'Amico risk stratification system divides patients into low, intermediate, and high-risk groups based on three key parameters: **Key Point:** PSA level, Gleason score, and TNM stage are the three pillars of risk stratification in prostate cancer. ### Poor Prognostic Factors | Factor | Threshold | Implication | |--------|-----------|-------------| | Gleason score | ≥ 8 (out of 10) | High-grade, aggressive disease; poor differentiation | | PSA level | > 20 ng/mL | Suggests higher tumor burden and/or extraprostatic disease | | TNM stage | T3, T4, or N1, M1 | Extraprostatic extension or metastatic disease | | Distant metastases | M1 | Metastatic disease; indicates systemic spread | ### Why PSA < 10 ng/mL is NOT a Poor Prognostic Factor **High-Yield:** PSA < 10 ng/mL is actually associated with **lower tumor burden** and is classified as **low-risk disease** in the D'Amico system. This is a **favorable** prognostic marker, not an adverse one. - PSA 0–10 ng/mL = Low risk (when combined with Gleason ≤ 6 and stage T1–T2a) - PSA 10–20 ng/mL = Intermediate risk - PSA > 20 ng/mL = High risk **Clinical Pearl:** In the patient presented (PSA 12, Gleason 7, T2b), the PSA of 12 ng/mL places him in the intermediate-risk category, not poor-risk. The intermediate Gleason score (7) and stage T2b are the concerning features here. ### Summary of Adverse Prognostic Indicators 1. Gleason score ≥ 8 — high-grade disease 2. PSA > 20 ng/mL — high tumor burden 3. T3, T4, or N1 disease — local/regional extension 4. M1 disease — distant metastases **Warning:** Do not confuse "PSA < 10" with "PSA > 20". The question asks which is NOT poor prognostic — the answer is the one that is actually favorable.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.